Latest News

• share
• favorite_border

In a small, investigator-initiated phase 2 study by Dana-Farber Cancer Institute investigators, a novel combination of an antibody-drug conjugate and an immune checkpoint inhibitor showed notable activity in pre-treated patients with a difficult-to-treat form of endometrial cancer. In this study, tumors were reduced in six out of 16 patients treated with the combination, including one case in which the cancer disappeared.

• share
• favorite_border

Numerous studies conducted by researchers at Dana-Farber Cancer Institute show promising results for patients with endometrial, lung, breast, prostate, and colorectal cancers.

• share
• favorite_border

Dana-Farber Cancer Institute has implemented an artificial intelligence (AI) application intended for general use in a medical center or hospital.

• share
• favorite_border

In a survey of more than 200 U.S. oncologists, vast majority indicate that oncologists should be able to explain how AI works to their patients. Respondents say AI developers, more than oncologists or hospitals, have responsibility for legal issues arising from AI use in cancer care.

• share
• favorite_border

Andrew E. Place, MD, PhD, has been named as Vice President, Pediatric Chief Medical Officer (CMO) at Dana-Farber Cancer Institute (within the Department of Pediatric Oncology) and Boston Children’s Hospital (within the Division of Hematology/Oncology) for the Dana-Farber/Boston Children’s Cancer and Blood Disorders Center.

• share
• favorite_border

The American Society of Clinical Oncology (ASCO) recognized Janet L. Abrahm, MD, FACP, FAAHPM, of Dana-Farber Cancer Institute and Brigham and Women’s Hospital, as a recipient of an ASCO Special Award, the Society’s highest honor.

• share
• favorite_border

For the fifth straight time, the American Nurses Credentialing Center (ANCC) has awarded Magnet® status to Dana-Farber Cancer Institute, recognizing excellence in nursing practice and patient care.

• share
• favorite_border

Dana-Farber Cancer Institute launched the Neuro-Inclusive Oncology Care and Empowerment Program, a psychosocial oncology program that is specialized for adults with intellectual and/or developmental disabilities (IDD).

• share
• favorite_border

Scott Armstrong, MD, PhD, has been named senior vice president for drug discovery and chief research strategy officer at Dana-Farber Cancer Institute. In this new role, he will lead Dana-Farber's institutional research strategy with an initial focus on therapeutic discovery work.

• share
• favorite_border

In the GENERATE study, 90% of those who viewed an online genetic education program chose to be tested for inherited predisposition to pancreatic cancer.

• share
• favorite_border

Dana-Farber Cancer Institute (Boston, MA, USA) and Gustave Roussy (Grand Paris, Villejuif, France) have announced that the third Transatlantic Exchange in Oncology Conference will address: Liquid Biopsy as an Emerging Approach in Precision Cancer Medicine.The meeting, supported by L’Institut Servier, will be held in-person (witha virtual attendance option) on April 12, 2024, at the Revere Hotel Boston Common and livestreamed virtually on Medscape’s platform.

• share
• favorite_border

The findings out of Dana-Farber Cancer Institute highlight that the mechanisms of immune modulation are different in patients treated with immunotherapy and anti-angiogenic combinations. The results also point to the role of tumor biology in the diversity and actions of tumor-infiltrating immune cells brought into action by these treatments. The findings might be important for predicting or understanding treatment outcomes in advanced kidney cancer.

• share
• favorite_border

Unintentional weight loss is associated with an increase in the risk of a cancer diagnosis within the coming year, according to a study from Dana-Farber Cancer Institute.

• share
• favorite_border

Researchers at Dana-Farber Cancer Institute and the University of Trento, Italy, have developed a blood test, described in Cancer Discovery, that can reliably detect neuroendocrine prostate cancer and differentiate it from castration-resistant prostate cancer-adenocarcinoma.

• share
• favorite_border

• Stapled lipopeptides successfully deter infection by the SARS-CoV-2 virus and reduce the severity of COVID-19 in tests with hamsters

• share
• favorite_border

George Demetri, MD, director of the Sarcoma Center at Dana-Farber Cancer Institute, is being awarded the prestigious J.E. Wallace Sterling Lifetime Achievement Award in Medicine from the Stanford Medicine Alumni Association (SMAA).

• share
• favorite_border

Patients with advanced prostate cancer with tumors harboring RB1 gene loss or neuroendocrine features often have a poor prognosis and limited treatment options.

• share
• favorite_border

Memorial Sloan Kettering Cancer Center (MSK) is proud to announce three innovative investigators as the recipients of this year’s Paul Marks Prize for Cancer Research.

• share
• favorite_border

Cabozantinib, which targets tumor cell growth and tumor blood vessel growth, sharply improved progression-free survival over placebo in patients with extra-pancreatic and pancreatic neuroendocrine tumors

• share
• favorite_border

Belzutifan significantly reduced the risk of progression of clear cell renal cell carcinoma (ccRCC), the most common type of kidney cancer, in patients previously treated with immune checkpoint inhibitors and anti-angiogenic therapies compared with everolimus in a phase 3 clinical trial.

• share
• favorite_border

Novel treatments, combination therapies, and personalized medicine headline several studies led by Dana-Farber Cancer Institute and presented for the first time at the European Society of Medical Oncology (ESMO) Congress 2023 in Madrid, Spain.

• share
• favorite_border

The Kraft Family Blood Donor Center, which provides lifesaving blood products to patients at Dana-Farber Cancer Institute and Brigham and Women’s Hospital, announced today that it has finished implementing a more inclusive blood donation process, in alignment with updated guidelines issued by the U.S. Food and Drug Administration (FDA) that will allow many gay and bisexual men to donate blood and platelets.

• share
• favorite_border

Do you know your risk for breast and ovarian cancer? How about steps you can take to reduce your chances of developing cancer or what a family history might mean for your risk of the disease?

• share
• favorite_border

Bradley Bernstein, MD, PhD, Chair of Cancer Biology at Dana-Farber Cancer Institute, has been elected to the National Academy of Medicine (NAM).

• share
• favorite_border

IDRs comprise a large percentage of the human proteome and are particularly important for nuclear proteins that govern our genomic architecture and gene expression.

• share
• favorite_border

• share
• favorite_border

The Pancreatic Cancer Action Network (PanCAN), a leading non-profit in the fight against pancreatic cancer, has awarded Dana-Farber Cancer Institute researchers William Freed-Pastor, MD, PhD, and Julien Dilly, MS, research grants of $250,000 and $150,000, respectively over a 2-year period, to support their crucial work in the field of pancreatic cancer research.

• share
• favorite_border

Researchers at Dana-Farber Cancer Institute have created an AI-based tool that uses tumor gene sequencing data to predict the primary source of a patient’s cancer. The study, published in in Nature Medicine, suggests that this predictive tool, called OncoNPC, could help guide treatment of cancer and improve outcomes in difficult to diagnose cases.

• share
• favorite_border

• share
• favorite_border

This case study by Dana-Farber gives evidence-based guidance for how to navigate decision-making for individual patients with metastatic hormone-sensitive prostate cancer.

• share
• favorite_border

Several phase 3 studies conducted by researchers from Dana-Farber Cancer Institute show promising results for patients with rectal, brain, and kidney cancers. The results of these studies, along with dozens of others led by Dana-Farber researchers, will be presented at the 2023 Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago.

• share
• favorite_border

A clinical trial, led by Dana-Farber Cancer Institute, has shown that a telephone-based weight loss program can help patients with breast cancer whose body mass index is in the overweight or obese range lower their weight by a meaningful degree.

• share
• favorite_border

Hundreds of attendees joined the 2nd Transatlantic Exchange program on Friday, 5 May 2023, in Paris, France. The day-long session focused on artificial intelligence (AI) and data science in oncology.

• share
• favorite_border

A targeted kinase inhibitor added to a two-drug immunotherapy combination slowed the progression of advanced kidney cancer in previously untreated patients, according to research published in The New England Journal of Medicine and led by an oncologist from Dana-Farber Cancer Institute.

• share
• favorite_border

The Linde Family Foundation has made a $10 million gift to launch the Center for Therapeutic Discovery at Dana-Farber Cancer Institute. This new center will be home to a new team devoted to the development of novel therapeutics for patients with rare and hard-to-treat cancers.

• share
• favorite_border

In the Nature Cancer study, researchers led by Dana-Farber's Himisha Beltran, MD, and Martin Bakht, PhD, found that PSMA expression is lower in liver metastases than in other parts of the body, regardless of expression of the androgen receptor. They also found that some tumors that test negative for the AR do express PSMA and that some AR-positive tumors don't – which led them to look for a control mechanism that doesn't involve the AR. Their search revealed that the HOXB13 protein as a key regulator of PSMA.

• share
• favorite_border

In this study led by Dana-Farber Cancer Institute, interim results of the combination of cabozantinib, a VEGF TKI, plus belzutifan, a HIF-2α inhibitor, show promising anti-tumor activity in this pre-treated patient group. The results suggest that the combination might fill and unmet need and provides a rationale for further study of combining a VEGF TKI and a HIF-2 inhibitor.

• share
• favorite_border

The second TransAtlantic Exchanges program between Dana-Farber Cancer Institute (Boston, MA, USA) and Gustave Roussy (Villejuif, France) will be held on May 5th in Paris and will focus on artificial intelligence (AI) and data science in oncology.

• share
• favorite_border

This study looks at what happens before the emergence of colorectal cancer mutations and finds not only evidence of fetal reprogramming that can initiate cancer, but also a protein, Sox9, that fuels that reprogramming.

• share
• favorite_border

A co-location model for cancer diagnostic services designed by researchers at Dana-Farber Cancer Institute has reported a reduction in the time it takes to diagnose cancer in a community health center in Boston, MA, that cares for a historically underserved populations.

• share
• favorite_border

Custom-made to attack cancer cells, CAR T-cell therapies have opened a new era in the treatment of human cancers, particularly, in hematologic malignancies. All too often, however, they display a frustrating trait inherited from the body's own immune system cells: a drastic loss of cancer-fighting fervor known as "exhaustion”.

• share
• favorite_border

In a new paper published in Science, Dana-Farber Cancer Institute researchers outline the complexities of young-onset colorectal cancer and the research needed to map out a path toward understanding it.

• share
• favorite_border

A new class of oral drugs can inhibit a wide range of SARS-CoV-2 variants, researchers report, potentially identifying new antiviral agents providing broad activity against the constantly emerging new strains of the COVID-19 virus

• share
• favorite_border

Dana-Farber is leading two studies to investigate novel treatment options for colorectal cancer patients. One study is looking at next-generation immunotherapy and the other is investigating CAR-T therapy in colorectal cancer.

• share
• favorite_border

This study shows vaccination against COVID-19 is an essential strategy to improve outcomes in this high-risk population. The results support guidelines that patients with cancer should receive at least 3 COVID-19 vaccine doses.

• share
• favorite_border

In a new study, researchers at Dana-Farber Cancer Institute used cryo-electron microscopy to reveal for the first time how one IAP, a protein called BIRC6, operates at a molecular level to inhibit programmed cell death.

• share
• favorite_border

The second season of Unraveled: A Dana-Farber Cancer Institute podcast is now available with six new episodes telling stories of the science and scientists behind some of the most important cancer discoveries, diving deep into the lab.